Web4 aug. 2024 · We earned nearly $240 million in revenue and recognized $312 million in non-GAAP operating expenses, resulting in a non-GAAP net loss of $81 million. These results were in line with our... Web11 mrt. 2024 · Ionis Pharmaceuticals has a 1 year low of $31.46 and a 1 year high of $48.82. The firm has a market capitalization of $4.97 billion, a price-to-earnings ratio of -18.29 and a beta of 0.57. The company has a debt-to-equity ratio of 2.06, a current ratio of 7.07 and a quick ratio of 7.00.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasted to Earn Q1 …
Web10 nov. 2024 · Ionis reported total revenues of $160 million in the second quarter, up … Web24 feb. 2024 · Net income of $111 million on a non-GAAP basis (1) and a net loss of … how has germany helped ukraine
Akcea Appoints Tracy Palmer Berns as Chief Compliance Officer
Web2 sep. 2024 · Ionis Pharmaceuticals (NASDAQ:IONS) has had a rough month with its share price down 8.3%. However, stock prices are... Web15 mrt. 2024 · Ionis Innovation. Antisense Technology; Pipeline; IonnovatIONS Podcast; … Web11 apr. 2024 · Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) had its price objective lifted by equities researchers at Morgan Stanley from $40.00 to $42.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley’s price objective indicates a potential upside of 13.79% from … highest rated lash serum